Efficient and Accurate KIR and HLA Genotyping with Massively Parallel Sequencing Data
Overview
Authors
Affiliations
Killer cell immunoglobulin like receptor (KIR) genes and human leukocyte antigen (HLA) genes play important roles in innate and adaptive immunity. They are highly polymorphic and cannot be genotyped with standard variant calling pipelines. Compared with HLA genes, many KIR genes are similar to each other in sequences and may be absent in the chromosomes. Therefore, although many tools have been developed to genotype HLA genes using common sequencing data, none of them work for KIR genes. Even specialized KIR genotypers could not resolve all the KIR genes. Here we describe T1K, a novel computational method for the efficient and accurate inference of KIR or HLA alleles from RNA-seq, whole-genome sequencing, or whole-exome sequencing data. T1K jointly considers alleles across all genotyped genes, so it can reliably identify present genes and distinguish homologous genes, including the challenging / genes. This model also benefits HLA genotyping, where T1K achieves high accuracy in benchmarks. Moreover, T1K can call novel single-nucleotide variants and process single-cell data. Applying T1K to tumor single-cell RNA-seq data, we found that expression was enriched in tumor-specific CD8 T cells. T1K may open the opportunity for HLA and KIR genotyping across various sequencing applications.
Locityper: targeted genotyping of complex polymorphic genes.
Prodanov T, Plender E, Seebohm G, Meuth S, Eichler E, Marschall T bioRxiv. 2025; .
PMID: 39990346 PMC: 11844405. DOI: 10.1101/2024.05.03.592358.
Jiang L, Baker S, Ceccarelil M, Guo Y HLA. 2025; 105(2):e70049.
PMID: 39957309 PMC: 11839181. DOI: 10.1111/tan.70049.
Geny: a genotyping tool for allelic decomposition of killer cell immunoglobulin-like receptor genes.
Zhou Q, Ghezelji M, Hari A, Ford M, Holley C, Sahinalp S Front Immunol. 2025; 15():1494995.
PMID: 39763645 PMC: 11701374. DOI: 10.3389/fimmu.2024.1494995.
Choi H, Choi E, Kim H, Baek I, Won A, Park S Clin Transplant Res. 2024; 38(4):294-308.
PMID: 39658458 PMC: 11732764. DOI: 10.4285/ctr.24.0055.
Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial.
Li R, Villa N, Yu X, Johnson J, Borjas G, Dhillon J Nat Med. 2024; 31(1):176-188.
PMID: 39521884 DOI: 10.1038/s41591-024-03324-9.